Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for DGX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -229.00M
March 31, 2026 -152.00M
December 31, 2025 -287.00M
September 30, 2025 -247.00M
June 30, 2025 -293.00M
March 31, 2025 -561.00M
December 31, 2024 -170.00M
September 30, 2024 1.77B
June 30, 2024 -363.00M
March 31, 2024 -153.00M
December 31, 2023 130.00M
September 30, 2023 -83.00M
June 30, 2023 189.00M
March 31, 2023 -76.00M
December 31, 2022 -545.00M
September 30, 2022 -474.00M
June 30, 2022 -242.00M
March 31, 2022 -471.00M
December 31, 2021 -369.00M
September 30, 2021 -38.00M
June 30, 2021 -1.567B
March 31, 2021 -566.00M
December 31, 2020 -820.00M
September 30, 2020 -52.00M
June 30, 2020 496.00M
Date Value
March 31, 2020 -891.00M
December 31, 2019 510.00M
September 30, 2019 -29.00M
June 30, 2019 -420.00M
March 31, 2019 164.00M
December 31, 2018 -81.00M
September 30, 2018 -154.00M
June 30, 2018 -191.00M
March 31, 2018 9.00M
December 31, 2017 -174.00M
September 30, 2017 -79.00M
June 30, 2017 -177.00M
March 31, 2017 -166.00M
December 31, 2016 -244.00M
September 30, 2016 -106.00M
June 30, 2016 -373.00M
March 31, 2016 32.00M
December 31, 2015 -148.00M
September 30, 2015 -176.00M
June 30, 2015 -1.031B
March 31, 2015 785.00M
December 31, 2014 -190.00M
September 30, 2014 -152.00M
June 30, 2014 -75.00M
March 31, 2014 509.00M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Labcorp Holdings, Inc. -919.90M
DaVita, Inc. -269.89M
OPKO Health, Inc. -13.03M
Psychemedics Corp. --
NeoGenomics, Inc. -12.24M